BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36097151)

  • 21. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
    Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
    Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous quantitation of cytokeratin-19 fragment and carcinoembryonic antigen in human serum via quantum dot-doped nanoparticles.
    Chen Z; Liang R; Guo X; Liang J; Deng Q; Li M; An T; Liu T; Wu Y
    Biosens Bioelectron; 2017 May; 91():60-65. PubMed ID: 27988480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Association of Carcinoembryonic Antigen and Cytokeratin-19 Fragments 21-1 Levels with One-Year Survival of Advanced Non-Small Cell Lung Carcinoma at Cipto Mangunkusumo Hospital: A Retrospective Cohort Study.
    Rumende CM; Sugianto GCK; Rinaldi I; Muhadi M
    Acta Med Indones; 2020 Apr; 52(2):140-146. PubMed ID: 32778628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorescence-based immunosensor using three-dimensional CNT network structure for sensitive and reproducible detection of oral squamous cell carcinoma biomarker.
    Song CK; Oh E; Kang MS; Shin BS; Han SY; Jung M; Lee ES; Yoon SY; Sung MM; Ng WB; Cho NJ; Lee H
    Anal Chim Acta; 2018 Oct; 1027():101-108. PubMed ID: 29866259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
    Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
    Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is CEA better than CYFRA 21-1 in the monitoring of squamous cell lung cancer progression?
    Lo Russo G; Franchi F; Seminara P
    Med Princ Pract; 2011; 20(2):200. PubMed ID: 21252581
    [No Abstract]   [Full Text] [Related]  

  • 30. Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma.
    Malhotra R; Urs AB; Chakravarti A; Kumar S; Gupta VK; Mahajan B
    Tumour Biol; 2016 Jul; 37(7):9263-71. PubMed ID: 26779624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
    Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
    Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-invasive bioassay of Cytokeratin Fragment 21.1 (Cyfra 21.1) protein in human saliva samples using immunoreaction method: An efficient platform for early-stage diagnosis of oral cancer based on biomedicine.
    Jafari M; Hasanzadeh M
    Biomed Pharmacother; 2020 Nov; 131():110671. PubMed ID: 32853907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score.
    Blankenburg F; Hatz R; Nagel D; Ankerst D; Reinmiedl J; Gruber C; Seidel D; Stieber P
    Tumour Biol; 2008; 29(4):272-7. PubMed ID: 18781099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
    Chantapet P; Riantawan P; Lebnak P; Getngern P
    J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
    Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
    J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An electronic biosensor based on semiconducting tetrazine polymer immobilizing matrix coated on rGO for carcinoembryonic antigen.
    Joshi S; Raj KA; Rao MR; Ghosh R
    Sci Rep; 2022 Feb; 12(1):3006. PubMed ID: 35194116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis.
    Park Y; Kim Y; Lee JH; Lee EY; Kim HS
    Arch Pathol Lab Med; 2011 Dec; 135(12):1570-5. PubMed ID: 22129186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
    Triphuridet N; Vidhyarkorn S; Worakitsitisatorn A; Sricharunrat T; Teerayathanakul N; Auewarakul C; Chungklay N; Krongthong W; Luengingkasoot S; Sornsamdang G; Patumanond J; Sritipsukho P
    Lung Cancer; 2018 Aug; 122():243-248. PubMed ID: 30032839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis.
    Pastor A; Menéndez R; Cremades MJ; Pastor V; Llopis R; Aznar J
    Eur Respir J; 1997 Mar; 10(3):603-9. PubMed ID: 9072992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.